Lv1
50 积分 2024-10-21 加入
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
4个月前
已关闭
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China
7个月前
已完结
Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
7个月前
已完结
Clinical Characteristics and Economic Burden of Asthma in China: A Multicenter Retrospective Study
7个月前
已完结
Medication management, health outcomes, and economic burden of severe asthma stratified by asthma control levels
7个月前
已关闭
Medication management, health outcomes, and economic burden of severe asthma stratified by asthma control levels
7个月前
已关闭
Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis
7个月前
已完结
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
9个月前
已完结
Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
9个月前
已完结
皖公网安备34019202002308
